Skip to content

Effect of clinical typing on the the rate of achieving target sUA of benzbromarone in lowering uric acid Randomized, Parallel and Controlled Clinical Trials

Effect of clinical typing on the the rate of achieving target sUA of benzbromarone in lowering uric acid Randomized, Parallel and Controlled Clinical Trials

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900026577
Enrollment
Unknown
Registered
2019-10-14
Start date
2018-10-15
Completion date
Unknown
Last updated
2019-10-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gout

Interventions

control group:Patients were selected according to indications and contraindications. The medication regimen was: benzbromarone 25mg QD + baking soda 1g tid
experimental group:On the premise of indications and contraindications, 24-hour urine test was performed on the patients and the patients with reduced uric acid excretion were selected. The prescripti

Sponsors

Affiliated Hospital of Qiingdao University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
17 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1) Aged 18~70 years old male; 2) conform to the diagnostic criteria of primary gout, 8.0 mg/dL (476 micromol/L) < serum uric acid < 9.7 mg/dL (576 umol/L); 3) voluntarily attend and sign informed consent.

Exclusion criteria

Exclusion criteria: 1) allergic to all drugs, foods or their ingredients, or allergic to symptoms or allergic constitution; 2) In patients with active liver disease or cirrhosis, or with abnormal liver function, serum alanine aminotransferase (ALT) and glutamic oxaloacetic aminotransferase (AST) exceeded the upper limit of normal range by 1.5 times; 3) patients with active gastrointestinal ulcer; 4) thyroid dysfunction; 5) glomerular filtration rate was <60ml/min; 6) Severe heart disease patients, such as: decompensated heart failure (NYHA stage III and IV); unstable angina pectoris; past 12 months with a history of myocardial infarction; 7) kidney stones, renal cysts, sponge kidney or other obstructive nephropathy; 8) patients with xanthine inuresis; 9) rheumatoid arthritis and other causes of joint disease requiring treatment; 10) azathioprine, 6-mercaptopurine, cyclosporine, cyclophosphamide, bizinamide, sulfamethoxazole, trimethoprim, theophylline, thiazide diuretics, aspirin (more than 325mg/day) or other salicylic acid substances, losartan, intravenous colchicine treatment; 11) patients with secondary hyperuricemia caused by hematological diseases, renal diseases or tumor radiotherapy and chemotherapy; 12) brain disease, abnormal judgement; mental illness can not cooperate; 13) alcoholics or drug addicts; 14) Pregnancy, breastfeeding or intentional pregnancy, women of childbearing age who do not use effective contraceptive measures (referring to intrauterine devices, oral contraceptives and obstructive measures); 15) during the first three months of the study, other clinical trials were included; 16) malignant tumor and active tuberculosis; 17) concurrent with other diseases, and the researchers believe that the effect of evaluation or compliance is poor; 18) those taking corticosteroids; 19) white blood cell count < 4 x 10^9/L, or platelets < 100 x 10^9/L, or hemoglobin 90g/L; 20) for any other reason, the researchers consider it inappropriate to participate in the trial; 21) acute gouty arthritis authors were found in the first 2 weeks and 2 weeks of elution.

Design outcomes

Primary

MeasureTime frame
Blood uric acid value;fraction excretion of uric acid;Target rates;

Secondary

MeasureTime frame
AST ALT;GLU;TG;TC;BUN;CR;Urinary system ultrasound;Ccr;

Countries

China

Contacts

Public ContactLi Changgui

Qingdao University

changguili@vip.163.com+86 13969620056

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026